{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:32:40Z","timestamp":1788931960278,"version":"build-2803163510"},"reference-count":247,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.ejmech.2021.113934","type":"journal-article","created":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T18:21:41Z","timestamp":1634840501000},"page":"113934","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["NO-HDAC dual inhibitors"],"prefix":"10.1016","volume":"227","author":[{"given":"Negar","family":"Omidkhah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razieh","family":"Ghodsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejmech.2021.113934_bib1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1586\/ecp.12.74","article-title":"Polypharmacology: drug discovery for the future","volume":"6","author":"Reddy","year":"2013","journal-title":"Expet Rev. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.ejmech.2021.113934_bib2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1017\/S1092852900000213","article-title":"Multifunctional drugs: a novel concept for psychopharmacology","volume":"14","author":"Stahl","year":"2009","journal-title":"CNS Spectr."},{"issue":"19","key":"10.1016\/j.ejmech.2021.113934_bib3","doi-asserted-by":"crossref","first-page":"7874","DOI":"10.1021\/jm5006463","article-title":"Polypharmacology: challenges and opportunities in drug discovery: miniperspective","volume":"57","author":"Anighoro","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"issue":"15","key":"10.1016\/j.ejmech.2021.113934_bib4","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S1359-6446(04)03163-0","article-title":"From magic bullets to designed multiple ligands","volume":"9","author":"Morphy","year":"2004","journal-title":"Drug Discov. Today"},{"issue":"11","key":"10.1016\/j.ejmech.2021.113934_bib5","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1517\/17460440903341705","article-title":"Promise and challenges in drug discovery and development of hybrid anticancer drugs","volume":"4","author":"Gediya","year":"2009","journal-title":"Expet Opin. Drug Discov."},{"issue":"10","key":"10.1016\/j.ejmech.2021.113934_bib6","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1021\/jm061371e","article-title":"Chemical insights in the concept of hybrid drugs: the antitumor effect of nitric oxide-donating aspirin involves a quinone methide but not nitric oxide nor aspirin","volume":"50","author":"Hulsman","year":"2007","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113934_bib7","series-title":"NCX4040, a Nitric Oxide (NO) Donating Form of Aspirin as a Potential Treatment for Prostate Cancer","author":"Chinnapaka","year":"2019"},{"issue":"3","key":"10.1016\/j.ejmech.2021.113934_bib8","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/BF00254428","article-title":"Hormone-independent, non-alkylating mechanism of cytotoxicity for estramustine","volume":"15","author":"Tew","year":"1987","journal-title":"Urol. Res."},{"issue":"6","key":"10.1016\/j.ejmech.2021.113934_bib9","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.clgc.2020.03.017","article-title":"Long-term castration-related outcomes in patients with high-risk localized prostate cancer treated with androgen deprivation therapy with or without docetaxel and estramustine in the UNICANCER GETUG-12 trial","volume":"18","author":"Dumont","year":"2020","journal-title":"Clin. Genitourin. Cancer"},{"issue":"39","key":"10.1016\/j.ejmech.2021.113934_bib10","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000004801","article-title":"Chemotherapy with or without estramustine for treatment of castration-resistant prostate cancer: a systematic review and meta-analysis","volume":"95","author":"Qin","year":"2016","journal-title":"Medicine"},{"issue":"10","key":"10.1016\/j.ejmech.2021.113934_bib11","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.yexcr.2011.03.001","article-title":"Protein nitration and nitrosylation by NO-donating aspirin in colon cancer cells: relevance to its mechanism of action","volume":"317","author":"Williams","year":"2011","journal-title":"Exp. Cell Res."},{"issue":"7","key":"10.1016\/j.ejmech.2021.113934_bib12","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1093\/carcin\/bgy049","article-title":"Nitric oxide-donating aspirin (NO-Aspirin) suppresses lung tumorigenesis in\u00a0vitro and in\u00a0vivo and these effects are associated with modulation of the EGFR signaling pathway","volume":"39","author":"Song","year":"2018","journal-title":"Carcinogenesis"},{"issue":"22","key":"10.1016\/j.ejmech.2021.113934_bib13","doi-asserted-by":"crossref","first-page":"13861","DOI":"10.1021\/acs.jmedchem.0c01400","article-title":"Platinum (IV)-estramustine multiaction prodrugs are effective antiproliferative agents against prostate cancer cells","volume":"63","author":"Karmakar","year":"2020","journal-title":"J.\u00a0Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2021.113934_bib14","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1021\/ar7000843","article-title":"Hybrid molecules with a dual mode of action: dream or reality?","volume":"41","author":"Meunier","year":"2008","journal-title":"Accounts Chem. Res."},{"issue":"13","key":"10.1016\/j.ejmech.2021.113934_bib15","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1096\/fj.02-0211hyp","article-title":"Two's company, three's a crowd: can H2S be the third endogenous gaseous transmitter?","volume":"16","author":"Wang","year":"2002","journal-title":"Faseb. J."},{"issue":"2","key":"10.1016\/j.ejmech.2021.113934_bib16","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.alit.2020.10.003","article-title":"Hydrogen sulfide as a novel biomarker of asthma and chronic obstructive pulmonary disease","volume":"70","author":"Suzuki","year":"2021","journal-title":"Allergol. Int."},{"key":"10.1016\/j.ejmech.2021.113934_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.657457","article-title":"Gaseous mediators as a key molecular targets for the development of gastrointestinal-safe anti-inflammatory pharmacology","volume":"12","author":"Danielak","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2021.113934_bib18","series-title":"Towards Gaseous Mediator Hybrid Drugs. Design of Hybrid Molecules for Drug Development","first-page":"47","author":"Gilmer","year":"2017"},{"key":"10.1016\/j.ejmech.2021.113934_bib19","article-title":"Role of hydrogen sulfide in the endocrine system","volume":"12","author":"Chen","year":"2021","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.ejmech.2021.113934_bib20","doi-asserted-by":"crossref","first-page":"101262","DOI":"10.1016\/j.arr.2021.101262","article-title":"Hydrogen sulfide in longevity and pathologies: inconsistency is malodorous","author":"Sokolov","year":"2021","journal-title":"Ageing Res. Rev."},{"issue":"2\u20133","key":"10.1016\/j.ejmech.2021.113934_bib21","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0005-2728(99)00016-X","article-title":"Mammalian nitric oxide synthases","volume":"1411","author":"Stuehr","year":"1999","journal-title":"Biochim. Biophys. Acta Bioenerg."},{"issue":"6","key":"10.1016\/j.ejmech.2021.113934_bib22","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.lfs.2003.10.042","article-title":"iNOS-mediated nitric oxide production and its regulation","volume":"75","author":"Aktan","year":"2004","journal-title":"Life Sci."},{"key":"10.1016\/j.ejmech.2021.113934_bib23","doi-asserted-by":"crossref","DOI":"10.1021\/acs.biochem.1c00276","article-title":"Revisiting nitric oxide signaling: where was it, and where is it going?","author":"Marletta","year":"2021","journal-title":"Biochemistry"},{"issue":"10","key":"10.1016\/j.ejmech.2021.113934_bib24","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/nrmicro1004","article-title":"Antimicrobial reactive oxygen and nitrogen species: concepts and controversies","volume":"2","author":"Fang","year":"2004","journal-title":"Nat. Rev. Microbiol."},{"issue":"1","key":"10.1016\/j.ejmech.2021.113934_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/emi.2016.87","article-title":"Endogenous nitric oxide accumulation is involved in the antifungal activity of Shikonin against Candida albicans","volume":"5","author":"Liao","year":"2016","journal-title":"Emerg. Microb. Infect."},{"issue":"9","key":"10.1016\/j.ejmech.2021.113934_bib26","doi-asserted-by":"crossref","DOI":"10.1099\/acmi.0.000154","article-title":"Antibacterial activity of high-dose nitric oxide against pulmonary Mycobacterium abscessus disease","volume":"2","author":"Bogdanovski","year":"2020","journal-title":"Access microbiology"},{"key":"10.1016\/j.ejmech.2021.113934_bib27","doi-asserted-by":"crossref","first-page":"101734","DOI":"10.1016\/j.redox.2020.101734","article-title":"Mitigation of the replication of SARS-CoV-2 by nitric oxide in\u00a0vitro","volume":"37","author":"Akaberi","year":"2020","journal-title":"Redox biology"},{"issue":"1","key":"10.1016\/j.ejmech.2021.113934_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virol.2009.09.007","article-title":"Dual effect of nitric oxide on SARS-CoV replication: viral RNA production and palmitoylation of the S protein are affected","volume":"395","author":"\u00c5kerstr\u00f6m","year":"2009","journal-title":"Virology"},{"issue":"4","key":"10.1016\/j.ejmech.2021.113934_bib29","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jhin.2016.03.011","article-title":"Barriers to uptake of antimicrobial advice in a UK hospital: a qualitative study","volume":"93","author":"Broom","year":"2016","journal-title":"J.\u00a0Hosp. Infect."},{"issue":"19","key":"10.1016\/j.ejmech.2021.113934_bib30","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1056\/NEJMra0904124","article-title":"Hospital-acquired infections due to gram-negative bacteria","volume":"362","author":"Peleg","year":"2010","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2021.113934_bib31","doi-asserted-by":"crossref","first-page":"101826","DOI":"10.1016\/j.redox.2020.101826","article-title":"Antimicrobial effects of nitric oxide in murine models of Klebsiella pneumonia","volume":"39","author":"Wiegand","year":"2021","journal-title":"Redox biology"},{"key":"10.1016\/j.ejmech.2021.113934_bib32","series-title":"Lifestyle-mediated Nitric Oxide Boost to Prevent SARS-CoV-2 Infection: A Perspective","author":"Kobayashi","year":"2021"},{"issue":"19","key":"10.1016\/j.ejmech.2021.113934_bib33","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1161\/CIRCULATIONAHA.119.043578","article-title":"S-nitrosylation of histone deacetylase 2 by neuronal nitric oxide synthase as a mechanism of diastolic dysfunction","volume":"143","author":"Yoon","year":"2021","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.ejmech.2021.113934_bib34","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.3390\/biom11071009","article-title":"Protein phosphorylation in cancer: role of nitric oxide signaling pathway","volume":"11","author":"Liu","year":"2021","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.ejmech.2021.113934_bib35","doi-asserted-by":"crossref","DOI":"10.1177\/1557988320903191","article-title":"The Yin Yang role of nitric oxide in prostate cancer","volume":"14","author":"Soni","year":"2020","journal-title":"Am. J. Men's Health"},{"issue":"3","key":"10.1016\/j.ejmech.2021.113934_bib36","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/carcin\/bgt034","article-title":"The yin and yang of nitric oxide in cancer progression","volume":"34","author":"Burke","year":"2013","journal-title":"Carcinogenesis"},{"issue":"1","key":"10.1016\/j.ejmech.2021.113934_bib37","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/(SICI)1097-0347(200001)22:1<71::AID-HED11>3.0.CO;2-G","article-title":"The yin and yang of nitric oxide: reflections on the physiology and pathophysiology of NO\u00b7. Head & Neck","volume":"22","author":"Bentz","year":"2000","journal-title":"Journal for the Sciences and Specialties of the Head and Neck"},{"key":"10.1016\/j.ejmech.2021.113934_bib38","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.niox.2019.09.005","article-title":"Nitric oxide and its derivatives in the cancer battlefield","volume":"93","author":"Kamm","year":"2019","journal-title":"Nitric Oxide"},{"issue":"1","key":"10.1016\/j.ejmech.2021.113934_bib39","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.sxmr.2015.10.004","article-title":"The role of PDE5 inhibitors and the NO\/cGMP pathway in cancer","volume":"4","author":"Peak","year":"2016","journal-title":"Sexual medicine reviews"},{"key":"10.1016\/j.ejmech.2021.113934_bib40","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1146\/annurev-biochem-050410-100030","article-title":"Structure and regulation of soluble guanylate cyclase","volume":"81","author":"Derbyshire","year":"2012","journal-title":"Annu. Rev. Biochem."},{"issue":"4","key":"10.1016\/j.ejmech.2021.113934_bib41","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1021\/bi9519718","article-title":"Spectral and kinetic studies on the activation of soluble guanylate cyclase by nitric oxide","volume":"35","author":"Stone","year":"1996","journal-title":"Biochemistry"},{"issue":"3","key":"10.1016\/j.ejmech.2021.113934_bib42","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1124\/pr.110.002907","article-title":"cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action","volume":"62","author":"Francis","year":"2010","journal-title":"Pharmacol. Rev."},{"issue":"3","key":"10.1016\/j.ejmech.2021.113934_bib43","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/1097-4652(200009)184:3<409::AID-JCP16>3.0.CO;2-K","article-title":"Molecular mechanism of cGMP-mediated smooth muscle relaxation","volume":"184","author":"Carvajal","year":"2000","journal-title":"J.\u00a0Cell. Physiol."},{"issue":"1","key":"10.1016\/j.ejmech.2021.113934_bib44","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.freeradbiomed.2011.04.010","article-title":"Nitric oxide signaling: classical, less classical, and nonclassical mechanisms","volume":"51","author":"Mart\u00ednez-Ruiz","year":"2011","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.ejmech.2021.113934_bib45","series-title":"Post-translational Modifications (PTM): Analytical Approaches, Signaling, Physiology and Pathophysiology\u2014Part I","author":"Tsikas","year":"2021"},{"issue":"2","key":"10.1016\/j.ejmech.2021.113934_bib46","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/cr.2013.151","article-title":"Protein post-translational modifications and regulation of pluripotency in human stem cells","volume":"24","author":"Wang","year":"2014","journal-title":"Cell Res."},{"issue":"8","key":"10.1016\/j.ejmech.2021.113934_bib47","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.3390\/cancers13081930","article-title":"Current methods of post-translational modification analysis and their applications in blood cancers","volume":"13","author":"Dunphy","year":"2021","journal-title":"Cancers"},{"issue":"20","key":"10.1016\/j.ejmech.2021.113934_bib48","doi-asserted-by":"crossref","first-page":"4632","DOI":"10.1002\/pmic.200900398","article-title":"Modification-specific proteomics: strategies for characterization of post-translational modifications using enrichment techniques","volume":"9","author":"Zhao","year":"2009","journal-title":"Proteomics"},{"issue":"10","key":"10.1016\/j.ejmech.2021.113934_bib49","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.bbapap.2016.06.007","article-title":"The world of protein acetylation","volume":"1864","author":"Drazic","year":"2016","journal-title":"Biochim. Biophys. Acta Protein Proteonomics"},{"key":"10.1016\/j.ejmech.2021.113934_bib50","first-page":"1","article-title":"Impact of phosphorylation on thermal stability of proteins","author":"Potel","year":"2021","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ejmech.2021.113934_bib51","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.cbpa.2021.02.017","article-title":"Past, present, and perspectives of protein N-terminal methylation","volume":"63","author":"Diaz","year":"2021","journal-title":"Curr. Opin. Chem. Biol."},{"issue":"5","key":"10.1016\/j.ejmech.2021.113934_bib52","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1002\/jcp.30143","article-title":"The important roles of protein SUMOylation in the occurrence and development of leukemia and clinical implications","volume":"236","author":"Zhao","year":"2021","journal-title":"J.\u00a0Cell. Physiol."},{"issue":"12","key":"10.1016\/j.ejmech.2021.113934_bib53","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/s41580-020-00294-x","article-title":"Global view of human protein glycosylation pathways and functions","volume":"21","author":"Schjoldager","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"5","key":"10.1016\/j.ejmech.2021.113934_bib54","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3390\/genes12050717","article-title":"UbiComb: a hybrid deep learning model for predicting plant-specific protein ubiquitylation sites","volume":"12","author":"Siraj","year":"2021","journal-title":"Genes"},{"issue":"16","key":"10.1016\/j.ejmech.2021.113934_bib55","doi-asserted-by":"crossref","first-page":"4928","DOI":"10.1046\/j.1432-1327.2000.01601.x","article-title":"Regulation of protein function by S-glutathiolation in response to oxidative and nitrosative stress","volume":"267","author":"Klatt","year":"2000","journal-title":"Eur. J. Biochem."},{"issue":"6","key":"10.1016\/j.ejmech.2021.113934_bib56","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0092-8674(01)00495-0","article-title":"Nitrosylation: the prototypic redox-based signaling mechanism","volume":"106","author":"Stamler","year":"2001","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.ejmech.2021.113934_bib57","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1021\/cb600439h","article-title":"Regulation and specificity of S-nitrosylation and denitrosylation","volume":"1","author":"Tannenbaum","year":"2006","journal-title":"ACS Chem. Biol."},{"issue":"7","key":"10.1016\/j.ejmech.2021.113934_bib58","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3390\/life11070705","article-title":"The role of protein S-nitrosylation in protein misfolding-associated diseases","volume":"11","author":"Ju","year":"2021","journal-title":"Life"},{"issue":"1","key":"10.1016\/j.ejmech.2021.113934_bib59","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.cbpa.2010.10.012","article-title":"The SNO-proteome: causation and classifications","volume":"15","author":"Seth","year":"2011","journal-title":"Curr. Opin. Chem. Biol."},{"issue":"3","key":"10.1016\/j.ejmech.2021.113934_bib60","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/FJC.0b013e3181b72c9f","article-title":"S-Nitrosylation of cardiac ion channels","volume":"54","author":"Gonzalez","year":"2009","journal-title":"J.\u00a0Cardiovasc. Pharmacol."},{"issue":"12","key":"10.1016\/j.ejmech.2021.113934_bib61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-019-2144-6","article-title":"Extensive protein S-nitrosylation associated with human pancreatic ductal adenocarcinoma pathogenesis","volume":"10","author":"Tan","year":"2019","journal-title":"Cell Death Dis."},{"issue":"7","key":"10.1016\/j.ejmech.2021.113934_bib62","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.3390\/antiox10071111","article-title":"Biological mechanisms of S-nitrosothiol formation and degradation: how is specificity of S-nitrosylation achieved?","volume":"10","author":"Massa","year":"2021","journal-title":"Antioxidants"},{"issue":"4","key":"10.1016\/j.ejmech.2021.113934_bib63","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S1471-4914(03)00028-5","article-title":"S-nitrosylation in health and disease","volume":"9","author":"Foster","year":"2003","journal-title":"Trends Mol. Med."},{"issue":"3","key":"10.1016\/j.ejmech.2021.113934_bib64","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1172\/JCI200524459","article-title":"NO\/redox disequilibrium in the failing heart and cardiovascular system","volume":"115","author":"Hare","year":"2005","journal-title":"J.\u00a0Clin. Invest."},{"issue":"9","key":"10.1016\/j.ejmech.2021.113934_bib65","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.3390\/cancers12092349","article-title":"Caveolin-1-mediated tumor suppression is linked to reduced HIF1\u03b1 S-Nitrosylation and transcriptional activity in hypoxia","volume":"12","author":"Sanhueza","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2021.113934_bib66","first-page":"4314","article-title":"Dynamic denitrosylation via S-nitrosoglutathione reductase regulates cardiovascular function","volume":"vol. 109","author":"Beigi","year":"2012"},{"key":"10.1016\/j.ejmech.2021.113934_bib67","doi-asserted-by":"crossref","first-page":"110096","DOI":"10.1016\/j.ecoenv.2019.110096","article-title":"Microcystins-LR induced apoptosis via S-nitrosylation of GAPDH in colorectal cancer cells","volume":"190","author":"Li","year":"2020","journal-title":"Ecotoxicol. Environ. Saf."},{"issue":"2","key":"10.1016\/j.ejmech.2021.113934_bib68","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.canlet.2012.03.009","article-title":"Protein S-nitrosylation and cancer","volume":"320","author":"Wang","year":"2012","journal-title":"Cancer Lett."},{"issue":"37","key":"10.1016\/j.ejmech.2021.113934_bib69","doi-asserted-by":"crossref","first-page":"26497","DOI":"10.1074\/jbc.R113.461368","article-title":"Causes and consequences of cysteine S-glutathionylation","volume":"288","author":"Grek","year":"2013","journal-title":"J.\u00a0Biol. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2021.113934_bib70","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/nm1119","article-title":"S-Glutathiolation by peroxynitrite activates SERCA during arterial relaxation by nitric oxide","volume":"10","author":"Adachi","year":"2004","journal-title":"Nat. Med."},{"issue":"16","key":"10.1016\/j.ejmech.2021.113934_bib71","doi-asserted-by":"crossref","first-page":"5362","DOI":"10.1021\/bi973153g","article-title":"Reaction between S-nitrosothiols and thiols: generation of nitroxyl (HNO) and subsequent chemistry","volume":"37","author":"Wong","year":"1998","journal-title":"Biochemistry"},{"issue":"3","key":"10.1016\/j.ejmech.2021.113934_bib72","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1096\/fj.05-4875fje","article-title":"S-glutathiolation by peroxynitrite of p21ras at cysteine-118 mediates its direct activation and downstream signaling in endothelial cells","volume":"20","author":"Clavreul","year":"2006","journal-title":"Faseb. J."},{"issue":"38","key":"10.1016\/j.ejmech.2021.113934_bib73","doi-asserted-by":"crossref","first-page":"12408","DOI":"10.1021\/bi9909445","article-title":"Peroxynitrite modification of protein thiols: oxidation, nitrosylation, and S-glutathiolation of functionally important cysteine residue (s) in the sarcoplasmic reticulum Ca-ATPase","volume":"38","author":"Viner","year":"1999","journal-title":"Biochemistry"},{"issue":"5","key":"10.1016\/j.ejmech.2021.113934_bib74","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ejps.2012.03.010","article-title":"S-Glutathionylation signaling in cell biology: progress and prospects","volume":"46","author":"Pastore","year":"2012","journal-title":"Eur. J. Pharmaceut. Sci."},{"issue":"11","key":"10.1016\/j.ejmech.2021.113934_bib75","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1016\/j.bcp.2008.02.026","article-title":"Inhibition of caspase-3 activity and activation by protein glutathionylation","volume":"75","author":"Huang","year":"2008","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.ejmech.2021.113934_bib76","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0003-9861(02)00468-X","article-title":"Identification of S-glutathionylated cellular proteins during oxidative stress and constitutive metabolism by affinity purification and proteomic analysis","volume":"406","author":"Lind","year":"2002","journal-title":"Arch. Biochem. Biophys."},{"issue":"12","key":"10.1016\/j.ejmech.2021.113934_bib77","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1073\/pnas.0307446101","article-title":"Nitric oxide, oxidants, and protein tyrosine nitration","volume":"101","author":"Radi","year":"2004","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"issue":"1","key":"10.1016\/j.ejmech.2021.113934_bib78","doi-asserted-by":"crossref","first-page":"H30","DOI":"10.1152\/ajpheart.00743.2003","article-title":"Dynamics of protein nitration in cells and mitochondria","volume":"286","author":"Aulak","year":"2004","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.ejmech.2021.113934_bib79","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.redox.2017.09.009","article-title":"Fundamentals on the biochemistry of peroxynitrite and protein tyrosine nitration","volume":"14","author":"Bartesaghi","year":"2018","journal-title":"Redox biology"},{"issue":"3","key":"10.1016\/j.ejmech.2021.113934_bib80","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/cbin.11301","article-title":"Tyrosine nitration as a key event of signal transduction that regulates functional state of the cell","volume":"45","author":"Sabadashka","year":"2021","journal-title":"Cell Biol. Int."},{"key":"10.1016\/j.ejmech.2021.113934_bib81","series-title":"Untargeted Discovery of Nitric Oxide-Modified Proteins","first-page":"327","author":"Deeb","year":"2010"},{"issue":"7","key":"10.1016\/j.ejmech.2021.113934_bib82","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1021\/pr900039c","article-title":"Protein tyrosine nitration: selectivity, physicochemical and biological consequences, denitration, and proteomics methods for the identification of tyrosine-nitrated proteins","volume":"8","author":"Abello","year":"2009","journal-title":"J.\u00a0Proteome Res."},{"issue":"8","key":"10.1016\/j.ejmech.2021.113934_bib83","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/nrd2222","article-title":"Peroxynitrite: biochemistry, pathophysiology and development of therapeutics","volume":"6","author":"Szab\u00f3","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"issue":"15","key":"10.1016\/j.ejmech.2021.113934_bib84","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1096\/fasebj.13.15.2311","article-title":"Nitric oxide induces tyrosine nitration and release of cytochrome c preceding an increase of mitochondrial transmembrane potential in macrophages","volume":"13","author":"Hortelano","year":"1999","journal-title":"Faseb. J."},{"key":"10.1016\/j.ejmech.2021.113934_bib85","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0076-6879(08)01211-1","article-title":"Nitrocytochrome c: synthesis, purification, and functional studies","volume":"441","author":"Souza","year":"2008","journal-title":"Methods Enzymol."},{"issue":"8","key":"10.1016\/j.ejmech.2021.113934_bib86","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1073\/pnas.0809279106","article-title":"Disruption of the M80-Fe ligation stimulates the translocation of cytochrome c to the cytoplasm and nucleus in nonapoptotic cells","volume":"106","author":"Godoy","year":"2009","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"issue":"1","key":"10.1016\/j.ejmech.2021.113934_bib87","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0306-4522(01)00571-1","article-title":"Coexistence of translocated cytochrome c and nitrated protein in neurons of the rat cerebral cortex after oxygen and glucose deprivation","volume":"111","author":"Alonso","year":"2002","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.ejmech.2021.113934_bib88","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1006\/abbi.1999.1202","article-title":"Tyrosine modifications and inactivation of active site manganese superoxide dismutase mutant (Y34F) by peroxynitrite","volume":"366","author":"MacMillan-Crow","year":"1999","journal-title":"Arch. Biochem. Biophys."},{"issue":"2","key":"10.1016\/j.ejmech.2021.113934_bib89","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.abb.2008.10.034","article-title":"Protein tyrosine nitration\u2014an update","volume":"484","author":"Ischiropoulos","year":"2009","journal-title":"Arch. Biochem. Biophys."},{"issue":"2","key":"10.1016\/j.ejmech.2021.113934_bib90","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1021\/ar300234c","article-title":"Protein tyrosine nitration: biochemical mechanisms and structural basis of functional effects","volume":"46","author":"Radi","year":"2013","journal-title":"Accounts Chem. Res."},{"issue":"2","key":"10.1016\/j.ejmech.2021.113934_bib91","doi-asserted-by":"crossref","first-page":"708","DOI":"10.3390\/v5020708","article-title":"Oxidative stress and HPV carcinogenesis","volume":"5","author":"De Marco","year":"2013","journal-title":"Viruses"},{"issue":"6","key":"10.1016\/j.ejmech.2021.113934_bib92","doi-asserted-by":"crossref","first-page":"E868","DOI":"10.1152\/ajpendo.00510.2010","article-title":"Nitrosative modifications of protein and lipid signaling molecules by reactive nitrogen species","volume":"299","author":"White","year":"2010","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.ejmech.2021.113934_bib93","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1161\/CIRCRESAHA.109.202077","article-title":"Cardiovascular consequences when nitric oxide and lipid signaling converge","volume":"105","author":"Rudolph","year":"2009","journal-title":"Circ. Res."},{"issue":"23","key":"10.1016\/j.ejmech.2021.113934_bib94","doi-asserted-by":"crossref","first-page":"15515","DOI":"10.1074\/jbc.R800004200","article-title":"Nitro-fatty acid formation and signaling","volume":"283","author":"Freeman","year":"2008","journal-title":"J.\u00a0Biol. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2021.113934_bib95","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.freeradbiomed.2009.10.046","article-title":"Activation of vascular endothelial nitric oxide synthase and heme oxygenase-1 expression by electrophilic nitro-fatty acids","volume":"48","author":"Khoo","year":"2010","journal-title":"Free Radic. Biol. Med."},{"issue":"29","key":"10.1016\/j.ejmech.2021.113934_bib96","doi-asserted-by":"crossref","first-page":"20450","DOI":"10.1074\/jbc.M602814200","article-title":"Reversible post-translational modification of proteins by nitrated fatty acids in\u00a0vivo","volume":"281","author":"Batthyany","year":"2006","journal-title":"J.\u00a0Biol. Chem."},{"issue":"16","key":"10.1016\/j.ejmech.2021.113934_bib97","doi-asserted-by":"crossref","first-page":"9112","DOI":"10.1039\/D1RA00275A","article-title":"Anticancer potential of nitric oxide (NO) in neuroblastoma treatment","volume":"11","author":"Gordon","year":"2021","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2021.113934_bib98","doi-asserted-by":"crossref","first-page":"113153","DOI":"10.1016\/j.ejmech.2021.113153","article-title":"Nitric oxide-donating and reactive oxygen species-responsive prochelators based on 8-hydroxyquinoline as anticancer agents","volume":"212","author":"Zhang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2021.113934_bib99","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3390\/vaccines9020094","article-title":"Current advances of nitric oxide in cancer and anticancer therapeutics","volume":"9","author":"Mintz","year":"2021","journal-title":"Vaccines"},{"issue":"2","key":"10.1016\/j.ejmech.2021.113934_bib100","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.yexcr.2017.04.003","article-title":"Nitric oxide donor augments antineoplastic effects of arginine deprivation in human melanoma cells","volume":"355","author":"Mayevska","year":"2017","journal-title":"Exp. Cell Res."},{"issue":"8","key":"10.1016\/j.ejmech.2021.113934_bib101","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/iub.1057","article-title":"NOS-2 signaling and cancer therapy","volume":"64","author":"Bian","year":"2012","journal-title":"IUBMB Life"},{"issue":"6","key":"10.1016\/j.ejmech.2021.113934_bib102","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1124\/mol.111.073585","article-title":"Restoring soluble guanylyl cyclase expression and function blocks the aggressive course of glioma","volume":"80","author":"Zhu","year":"2011","journal-title":"Mol. Pharmacol."},{"issue":"2","key":"10.1016\/j.ejmech.2021.113934_bib103","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0304-3835(01)00788-1","article-title":"The bradykinin\/soluble guanylate cyclase signaling pathway is impaired in androgen-independent prostate cancer cells","volume":"177","author":"Chen","year":"2002","journal-title":"Cancer Lett."},{"issue":"4","key":"10.1016\/j.ejmech.2021.113934_bib104","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0125518","article-title":"Elevation of soluble guanylate cyclase suppresses proliferation and survival of human breast cancer cells","volume":"10","author":"Wen","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2021.113934_bib105","first-page":"296","article-title":"Maturation, inactivation, and recovery mechanisms of soluble guanylyl cyclase","author":"Stuehr","year":"2021","journal-title":"J.\u00a0Biol. Chem."},{"issue":"7","key":"10.1016\/j.ejmech.2021.113934_bib106","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1515\/hsz-2018-0155","article-title":"From molecules to patients: exploring the therapeutic role of soluble guanylate cyclase stimulators","volume":"399","author":"Sandner","year":"2018","journal-title":"Biol. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2021.113934_bib107","doi-asserted-by":"crossref","DOI":"10.1051\/bmdcn\/2017070205","article-title":"YC-1 induces G0\/G1 phase arrest and mitochondria-dependent apoptosis in cisplatin-resistant human oral cancer CAR cells","volume":"7","author":"Lee","year":"2017","journal-title":"Biomedicine"},{"key":"10.1016\/j.ejmech.2021.113934_bib108","series-title":"Soluble Guanylate Cyclase Stimulators and Activators. Reactive Oxygen Species","first-page":"355","author":"Sandner","year":"2018"},{"issue":"1","key":"10.1016\/j.ejmech.2021.113934_bib109","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0190628","article-title":"Soluble guanylate cyclase stimulation reduces oxidative stress in experimental Chronic Obstructive Pulmonary Disease","volume":"13","author":"Paul","year":"2018","journal-title":"PLoS One"},{"issue":"21","key":"10.1016\/j.ejmech.2021.113934_bib110","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1001\/jama.2015.15734","article-title":"Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED randomized trial","volume":"314","author":"Gheorghiade","year":"2015","journal-title":"Jama"},{"key":"10.1016\/j.ejmech.2021.113934_bib111","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.canlet.2016.12.020","article-title":"Soluble guanylate cyclase stimulators increase sensitivity to cisplatin in head and neck squamous cell carcinoma cells","volume":"389","author":"Tuttle","year":"2017","journal-title":"Cancer Lett."},{"issue":"5","key":"10.1016\/j.ejmech.2021.113934_bib112","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0064189","article-title":"A\u00a0peptide against soluble guanylyl cyclase \u03b11: a new approach to treating prostate cancer","volume":"8","author":"Gao","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.ejmech.2021.113934_bib113","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1093\/jnci\/59.6.1741","article-title":"Stimulation of soluble guanylate cyclase activity and cellular accumulation of cyclic guanosine 3\u2032, 5\u2032-monophosphate by the carcinogen 4-nitroquinoline 1-oxide: brief communication","volume":"59","author":"DeRubertis","year":"1977","journal-title":"J.\u00a0Natl. Cancer Inst."},{"issue":"2","key":"10.1016\/j.ejmech.2021.113934_bib114","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/JLB.MR0519-143R","article-title":"Phenotypic impacts of CSF1R deficiencies in humans and model organisms","volume":"107","author":"Hume","year":"2020","journal-title":"J.\u00a0Leukoc. Biol."},{"issue":"12","key":"10.1016\/j.ejmech.2021.113934_bib115","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1093\/carcin\/bgq172","article-title":"Reciprocal activation of macrophages and breast carcinoma cells by nitric oxide and colony-stimulating factor-1","volume":"31","author":"Lin","year":"2010","journal-title":"Carcinogenesis"},{"issue":"2","key":"10.1016\/j.ejmech.2021.113934_bib116","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.niox.2008.04.021","article-title":"Nitric oxide, apoptosis and macrophage polarization during tumor progression","volume":"19","author":"Weigert","year":"2008","journal-title":"Nitric Oxide"},{"key":"10.1016\/j.ejmech.2021.113934_bib117","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3389\/fphys.2013.00144","article-title":"Macrophage-tumor cell interactions regulate the function of nitric oxide","volume":"4","author":"Rahat","year":"2013","journal-title":"Front. Physiol."},{"issue":"3","key":"10.1016\/j.ejmech.2021.113934_bib118","first-page":"727","article-title":"PD-1\/PD-L1 pathway: current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"American journal of cancer research"},{"issue":"1","key":"10.1016\/j.ejmech.2021.113934_bib119","first-page":"1","article-title":"Immune checkpoint inhibitors of PD-L1 as cancer therapeutics","volume":"12","author":"Akinleye","year":"2019","journal-title":"J.\u00a0Hematol. Oncol."},{"issue":"7","key":"10.1016\/j.ejmech.2021.113934_bib120","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA oncology"},{"key":"10.1016\/j.ejmech.2021.113934_bib121","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.2147\/COPD.S214610","article-title":"Effect of PD-1 inhibitor on exhaled nitric oxide and pulmonary function in non-small cell lung cancer patients with and without COPD","volume":"14","author":"Suzuki","year":"2019","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"issue":"5","key":"10.1016\/j.ejmech.2021.113934_bib122","doi-asserted-by":"crossref","first-page":"5683","DOI":"10.1002\/jcp.27411","article-title":"Cyclooxygenase-2 in cancer: a review","volume":"234","author":"Hashemi Goradel","year":"2019","journal-title":"J.\u00a0Cell. Physiol."},{"key":"10.1016\/j.ejmech.2021.113934_bib123","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.redox.2015.09.022","article-title":"Mechanisms of hypoxia-induced immune escape in cancer and their regulation by nitric oxide","volume":"5","author":"Graham","year":"2015","journal-title":"Redox biology"},{"issue":"9","key":"10.1016\/j.ejmech.2021.113934_bib124","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3390\/antiox8090407","article-title":"Nitric oxide-mediated enhancement and reversal of resistance of anticancer therapies","volume":"8","author":"Hays","year":"2019","journal-title":"Antioxidants"},{"key":"10.1016\/j.ejmech.2021.113934_bib125","series-title":"Abstract A202: Evaluating the Combination of Anti-PD-1 and Nitric Oxide Synthase Inhibition Therapy in 12 Triple-Negative Breast Cancer Patient-Derived Xenografts Using a Human-Derived Immune System Model","author":"Davila-Gonzalez","year":"2018"},{"key":"10.1016\/j.ejmech.2021.113934_bib126","series-title":"Abstract C181: RRx-001 Combined with Anti-PD-L1 Antibody Increases the Complete Response Rate in a Preclinical Myeloma Model","author":"Knox","year":"2015"},{"key":"10.1016\/j.ejmech.2021.113934_bib127","first-page":"3","article-title":"Phosphodiesterase diversity and signal processing within cAMP signaling networks","author":"Neves-Zaph","year":"2017","journal-title":"Phosphodiesterases: CNS Functions and Diseases"},{"key":"10.1016\/j.ejmech.2021.113934_bib128","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.pharmthera.2014.10.003","article-title":"PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer","volume":"147","author":"Das","year":"2015","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.ejmech.2021.113934_bib129","first-page":"257","article-title":"Sildenafil, a type-5 CGMP phosphodiesterase inhibitor, specifically amplifies endogenous cGMP-dependent relaxation in rabbit corpus cavernosum smooth muscle in\u00a0vitro","volume":"160","author":"Chuang","year":"1998","journal-title":"J.\u00a0Urol."},{"key":"10.1016\/j.ejmech.2021.113934_bib130","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.ejmech.2018.03.046","article-title":"Inhibitors of phosphodiesterase as cancer therapeutics","volume":"150","author":"Peng","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"5","key":"10.1016\/j.ejmech.2021.113934_bib131","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1517\/13543784.11.5.587","article-title":"Nitric oxide donor drugs: current status and future trends","volume":"11","author":"Webb","year":"2002","journal-title":"Expet Opin. Invest. Drugs"},{"issue":"2","key":"10.1016\/j.ejmech.2021.113934_bib132","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.pharmthera.2004.11.011","article-title":"Nitric oxide and penile erectile function","volume":"106","author":"Toda","year":"2005","journal-title":"Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.ejmech.2021.113934_bib133","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2174\/2211738507666190429111306","article-title":"Controlled delivery of nitric oxide for cancer therapy","volume":"7","author":"Alimoradi","year":"2019","journal-title":"Pharm. Nanotechnol."},{"key":"10.1016\/j.ejmech.2021.113934_bib134","first-page":"94","volume":"vol. 9","author":"Mintz","year":"2021"},{"issue":"5","key":"10.1016\/j.ejmech.2021.113934_bib135","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1021\/acssensors.1c00051","article-title":"Sensing nitric oxide in cells: historical technologies and future outlook","volume":"6","author":"Almeida","year":"2021","journal-title":"ACS Sens."},{"issue":"3","key":"10.1016\/j.ejmech.2021.113934_bib136","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.lungcan.2014.01.001","article-title":"Randomized, double-blind phase II study to compare nitroglycerin plus oral vinorelbine plus cisplatin with oral vinorelbine plus cisplatin alone in patients with stage IIIB\/IV non-small cell lung cancer (NSCLC)","volume":"83","author":"Reinmuth","year":"2014","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.ejmech.2021.113934_bib137","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00395-011-0240-6","article-title":"Vascular endothelial dysfunction in Duchenne muscular dystrophy is restored by bradykinin through upregulation of eNOS and nNOS","volume":"107","author":"Dabir\u00e9","year":"2012","journal-title":"Basic Res. Cardiol."},{"issue":"1","key":"10.1016\/j.ejmech.2021.113934_bib138","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2174\/157016112798829760","article-title":"The role of nitric oxide on endothelial function","volume":"10","author":"Tousoulis","year":"2012","journal-title":"Curr. Vasc. Pharmacol."},{"key":"10.1016\/j.ejmech.2021.113934_bib139","first-page":"147","article-title":"Vascular nitric oxide: formation and function","volume":"1","author":"Jin","year":"2010","journal-title":"Hematol. Res. Rev."},{"issue":"1","key":"10.1016\/j.ejmech.2021.113934_bib140","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1152\/physrev.2001.81.1.209","article-title":"Physiology of nitric oxide in skeletal muscle","volume":"81","author":"Stamler","year":"2001","journal-title":"Physiol. Rev."},{"issue":"5","key":"10.1016\/j.ejmech.2021.113934_bib141","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/sj.bjp.0704569","article-title":"NO as a signalling molecule in the nervous system","volume":"135","author":"Esplugues","year":"2002","journal-title":"Br. J. Pharmacol."},{"issue":"3\u20134","key":"10.1016\/j.ejmech.2021.113934_bib142","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.niox.2009.08.002","article-title":"Nitric oxide and repair of skeletal muscle injury","volume":"21","author":"Filippin","year":"2009","journal-title":"Nitric Oxide"},{"issue":"5","key":"10.1016\/j.ejmech.2021.113934_bib143","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1091\/mbc.11.5.1859","article-title":"A\u00a0role for nitric oxide in muscle repair: nitric oxide\u2013mediated activation of muscle satellite cells","volume":"11","author":"Anderson","year":"2000","journal-title":"Mol. Biol. Cell"},{"issue":"12","key":"10.1016\/j.ejmech.2021.113934_bib144","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.exger.2008.09.005","article-title":"Supplemental nitric oxide augments satellite cell activity on cultured myofibers from aged mice","volume":"43","author":"Betters","year":"2008","journal-title":"Exp. Gerontol."},{"issue":"1","key":"10.1016\/j.ejmech.2021.113934_bib145","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/cvr\/cvq035","article-title":"The histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces cardiac arrhythmias in dystrophic mice","volume":"87","author":"Colussi","year":"2010","journal-title":"Cardiovasc. Res."},{"issue":"1","key":"10.1016\/j.ejmech.2021.113934_bib146","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1073\/pnas.0608277104","article-title":"Nitric oxide release combined with nonsteroidal antiinflammatory activity prevents muscular dystrophy pathology and enhances stem cell therapy","volume":"104","author":"Brunelli","year":"2007","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"issue":"1","key":"10.1016\/j.ejmech.2021.113934_bib147","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.nbd.2005.02.010","article-title":"L-arginine improves dystrophic phenotype in mdx mice","volume":"20","author":"Voisin","year":"2005","journal-title":"Neurobiol. Dis."},{"issue":"24","key":"10.1016\/j.ejmech.2021.113934_bib148","doi-asserted-by":"crossref","first-page":"5114","DOI":"10.1242\/jcs.03300","article-title":"Ex\u00a0vivo treatment with nitric oxide increases mesoangioblast therapeutic efficacy in muscular dystrophy","volume":"119","author":"Sciorati","year":"2006","journal-title":"J.\u00a0Cell Sci."},{"issue":"4","key":"10.1016\/j.ejmech.2021.113934_bib149","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.nurt.2008.08.013","article-title":"Approaching a new age in Duchenne muscular dystrophy treatment","volume":"5","author":"Wagner","year":"2008","journal-title":"Neurotherapeutics"},{"issue":"18","key":"10.1016\/j.ejmech.2021.113934_bib150","doi-asserted-by":"crossref","first-page":"7617","DOI":"10.1021\/acs.jmedchem.6b01672","article-title":"Nitric oxide donor-based cancer therapy: advances and prospects","volume":"60","author":"Huang","year":"2017","journal-title":"J.\u00a0Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2021.113934_bib151","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-019-1089-9","article-title":"Role of hypoxia in cancer therapy by regulating the tumor microenvironment","volume":"18","author":"Jing","year":"2019","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.ejmech.2021.113934_bib152","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2014.07.014","article-title":"Nitric oxide in cancer metastasis","volume":"353","author":"Cheng","year":"2014","journal-title":"Cancer Lett."},{"issue":"12","key":"10.1016\/j.ejmech.2021.113934_bib153","first-page":"4701","article-title":"Potentiation of nitric oxide-induced apoptosis of MDA-MB-468 cells by farnesyltransferase inhibitor: implications in breast cancer","volume":"61","author":"Pervin","year":"2001","journal-title":"Cancer Res."},{"issue":"29","key":"10.1016\/j.ejmech.2021.113934_bib154","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1038\/sj.onc.1207655","article-title":"Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-\u03ba B and inhibition of Bcl-xl expression","volume":"23","author":"Huerta-Yepez","year":"2004","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.ejmech.2021.113934_bib155","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/med.20092","article-title":"Nitric oxide, a double edged sword in cancer biology: searching for therapeutic opportunities","volume":"27","author":"Mocellin","year":"2007","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2021.113934_bib156","doi-asserted-by":"crossref","first-page":"110981","DOI":"10.1016\/j.jinorgbio.2019.110981","article-title":"Vorinostat and Belinostat, hydroxamate-based anti-cancer agents, are nitric oxide donors","volume":"206","author":"Kenny","year":"2020","journal-title":"J.\u00a0Inorg. Biochem."},{"issue":"3","key":"10.1016\/j.ejmech.2021.113934_bib157","doi-asserted-by":"crossref","first-page":"424","DOI":"10.7150\/ijms.30154","article-title":"Histone deacetylases (HDACs) guided novel therapies for T-cell lymphomas","volume":"16","author":"Zhang","year":"2019","journal-title":"Int. J. Med. Sci."},{"issue":"7","key":"10.1016\/j.ejmech.2021.113934_bib158","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/sj.bjp.0701504","article-title":"Ruthenium complexes as nitric oxide scavengers: a potential therapeutic approach to nitric oxide-mediated diseases","volume":"122","author":"Fricker","year":"1997","journal-title":"Br. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.ejmech.2021.113934_bib159","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1021\/ic020219+","article-title":"Ruthenium (III) polyaminocarboxylate complexes: efficient and effective nitric oxide scavengers","volume":"42","author":"Cameron","year":"2003","journal-title":"Inorg. Chem."},{"issue":"13","key":"10.1016\/j.ejmech.2021.113934_bib160","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1039\/b001631o","article-title":"Hydroxamic acids are nitric oxide donors. Facile formation of ruthenium (II)-nitrosyls and NO-mediated activation of guanylate cyclase by hydroxamic acids","author":"Marmion","year":"2000","journal-title":"Chem. Commun."},{"issue":"5","key":"10.1016\/j.ejmech.2021.113934_bib161","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2183\/pjab.93.019","article-title":"Chemical and structural biology of protein lysine deacetylases","volume":"93","author":"Yoshida","year":"2017","journal-title":"Proceedings of the Japan Academy, Series B."},{"key":"10.1016\/j.ejmech.2021.113934_bib162","first-page":"13","article-title":"The biology of HDAC in cancer: the nuclear and epigenetic components","author":"Hagelkruys","year":"2011","journal-title":"Histone Deacetylases: the Biology and Clinical Implication"},{"issue":"1","key":"10.1016\/j.ejmech.2021.113934_bib163","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ccell.2017.06.008","article-title":"HDAC inhibitors finally open up: chromatin accessibility signatures of CTCL","volume":"32","author":"Ott","year":"2017","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.ejmech.2021.113934_bib164","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.molcel.2008.07.002","article-title":"Lysine acetylation: codified crosstalk with other posttranslational modifications","volume":"31","author":"Yang","year":"2008","journal-title":"Mol. Cell"},{"issue":"6","key":"10.1016\/j.ejmech.2021.113934_bib165","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/med.21437","article-title":"The search for potent, small-molecule HDACIs in cancer treatment: a decade after vorinostat","volume":"37","author":"Zagni","year":"2017","journal-title":"Med. Res. Rev."},{"issue":"12","key":"10.1016\/j.ejmech.2021.113934_bib166","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.3390\/ijms19123952","article-title":"Epigenetic targeting of autophagy via HDAC inhibition in tumor cells: role of p53","volume":"19","author":"Mrakovcic","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2021.113934_bib167","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/bs.acr.2018.02.006","article-title":"Advances and challenges of HDAC inhibitors in cancer therapeutics","volume":"138","author":"McClure","year":"2018","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.ejmech.2021.113934_bib168","doi-asserted-by":"crossref","first-page":"112648","DOI":"10.1016\/j.ejmech.2020.112648","article-title":"Design, synthesis and biological evaluation of novel HDAC inhibitors with improved pharmacokinetic profile in breast cancer","volume":"205","author":"Yao","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2021.113934_bib169","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/j.ejmech.2010.02.030","article-title":"Inside HDAC with HDAC inhibitors","volume":"45","author":"Bertrand","year":"2010","journal-title":"Eur. J. Med. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2021.113934_bib170","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1021\/jm7011408","article-title":"Histone deacetylase inhibitors: from bench to clinic","volume":"51","author":"Paris","year":"2008","journal-title":"J.\u00a0Med. Chem."},{"issue":"14","key":"10.1016\/j.ejmech.2021.113934_bib171","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.3390\/cancers13143575","article-title":"HDAC inhibitors: dissecting mechanisms of action to counter tumor heterogeneity","volume":"13","author":"Karagiannis","year":"2021","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.ejmech.2021.113934_bib172","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/nrm2346","article-title":"The Rpd3\/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men","volume":"9","author":"Yang","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"3","key":"10.1016\/j.ejmech.2021.113934_bib173","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/med.20024","article-title":"Histone deacetylation in epigenetics: an attractive target for anticancer therapy","volume":"25","author":"Mai","year":"2005","journal-title":"Med. Res. Rev."},{"issue":"7","key":"10.1016\/j.ejmech.2021.113934_bib174","doi-asserted-by":"crossref","first-page":"757","DOI":"10.7150\/ijbs.9067","article-title":"Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications","volume":"10","author":"Li","year":"2014","journal-title":"Int. J. Biol. Sci."},{"issue":"4","key":"10.1016\/j.ejmech.2021.113934_bib175","doi-asserted-by":"crossref","first-page":"634","DOI":"10.3390\/cancers13040634","article-title":"Anticancer therapy with HDAC inhibitors: mechanism-based combination strategies and future perspectives","volume":"13","author":"Jenke","year":"2021","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.ejmech.2021.113934_bib176","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.nmd.2016.07.002","article-title":"Histological effects of givinostat in boys with Duchenne muscular dystrophy","volume":"26","author":"Bettica","year":"2016","journal-title":"Neuromuscul. Disord."},{"issue":"10","key":"10.1016\/j.ejmech.2021.113934_bib177","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/nm1479","article-title":"Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors","volume":"12","author":"Minetti","year":"2006","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.ejmech.2021.113934_bib178","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2119\/molmed.2013.00011","article-title":"Preclinical studies in the mdx mouse model of duchenne muscular dystrophy with the histone deacetylase inhibitor givinostat","volume":"19","author":"Consalvi","year":"2013","journal-title":"Mol. Med."},{"key":"10.1016\/j.ejmech.2021.113934_bib179","first-page":"220","article-title":"The potential of epigenetic therapies in neurodegenerative diseases","volume":"5","author":"Copped\u00e8","year":"2014","journal-title":"Front. Genet."},{"issue":"1","key":"10.1016\/j.ejmech.2021.113934_bib180","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1378\/chest.129.1.151","article-title":"Reduced histone deacetylase in COPD: clinical implications","volume":"129","author":"Barnes","year":"2006","journal-title":"Chest"},{"issue":"9","key":"10.1016\/j.ejmech.2021.113934_bib181","doi-asserted-by":"crossref","first-page":"4955","DOI":"10.1096\/fj.201701518R","article-title":"Genetic ablation of histone deacetylase 2 leads to lung cellular senescence and lymphoid follicle formation in COPD\/emphysema","volume":"32","author":"Sundar","year":"2018","journal-title":"Faseb. J."},{"issue":"1","key":"10.1016\/j.ejmech.2021.113934_bib182","first-page":"1","article-title":"Lymphocyte senescence in COPD is associated with decreased histone deacetylase 2 expression by pro-inflammatory lymphocytes","volume":"16","author":"Hodge","year":"2015","journal-title":"Respir. Res."},{"key":"10.1016\/j.ejmech.2021.113934_bib183","article-title":"Histone deacetylase 6 mediated NALP3 inflammasome activation contributes to dopaminergic injury in experimental models of Parkinson disease","volume":"9","author":"Yan","year":"2018","journal-title":"\u4e2d\u56fd\u836f\u7406\u5b66\u4e0e\u6bd2\u7406\u5b66\u6742\u5fd7."},{"issue":"14","key":"10.1016\/j.ejmech.2021.113934_bib184","doi-asserted-by":"crossref","first-page":"10678","DOI":"10.1074\/jbc.M109.057836","article-title":"Histone deacetylase inhibitor valproic acid inhibits cancer cell proliferation via down-regulation of the alzheimer amyloid precursor protein","volume":"285","author":"Venkataramani","year":"2010","journal-title":"J.\u00a0Biol. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2021.113934_bib185","doi-asserted-by":"crossref","first-page":"62","DOI":"10.4331\/wjbc.v11.i2.62","article-title":"Zepeda-Cervantes J. Epigenetic basis of Alzheimer disease","volume":"11","author":"Tecalco-Cruz","year":"2020","journal-title":"World J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2021.113934_bib186","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.phrs.2010.02.014","article-title":"Histone deacetylase inhibitors: keeping momentum for neuromuscular and cardiovascular diseases treatment","volume":"62","author":"Colussi","year":"2010","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2021.113934_bib187","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.yjmcc.2019.04.012","article-title":"Epigenetic therapies in heart failure","volume":"130","author":"Alexanian","year":"2019","journal-title":"J.\u00a0Mol. Cell. Cardiol."},{"issue":"5","key":"10.1016\/j.ejmech.2021.113934_bib188","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.4049\/jimmunol.0901467","article-title":"Histone deacetylase inhibitors suppress inflammatory activation of rheumatoid arthritis patient synovial macrophages and tissue","volume":"184","author":"Grabiec","year":"2010","journal-title":"J.\u00a0Immunol."},{"issue":"12","key":"10.1016\/j.ejmech.2021.113934_bib189","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s00011-016-0984-4","article-title":"Therapeutic effects of histone deacetylase inhibitors in a murine asthma model","volume":"65","author":"Ren","year":"2016","journal-title":"Inflamm. Res."},{"issue":"7","key":"10.1016\/j.ejmech.2021.113934_bib190","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.str.2004.04.012","article-title":"Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases","volume":"12","author":"Somoza","year":"2004","journal-title":"Structure"},{"issue":"6","key":"10.1016\/j.ejmech.2021.113934_bib191","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.jmgm.2007.07.002","article-title":"Pharmacophore modeling and virtual screening studies to design some potential histone deacetylase inhibitors as new leads","volume":"26","author":"Vadivelan","year":"2008","journal-title":"J.\u00a0Mol. Graph. Model."},{"key":"10.1016\/j.ejmech.2021.113934_bib192","doi-asserted-by":"crossref","first-page":"128286","DOI":"10.1016\/j.bmcl.2021.128286","article-title":"Discovery of novel pyrazolopyrimidine derivatives as potent mTOR\/HDAC bi-functional inhibitors via pharmacophore-merging strategy","volume":"49","author":"Zhang","year":"2021","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"4","key":"10.1016\/j.ejmech.2021.113934_bib193","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1161\/ATVBAHA.110.214478","article-title":"Smad-interacting protein-1 and MicroRNA 200 family define a nitric oxide\u2013dependent molecular circuitry involved in embryonic stem cell mesendoderm differentiation","volume":"31","author":"Rosati","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ejmech.2021.113934_bib194","first-page":"1","article-title":"Nitric oxide-related gene and microRNA expression in peripheral blood in pregnancy vary by self-reported race","author":"Manuck","year":"2021","journal-title":"Epigenetics"},{"issue":"3","key":"10.1016\/j.ejmech.2021.113934_bib195","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.pharmthera.2009.05.003","article-title":"NO sparks off chromatin: tales of a multifaceted epigenetic regulator","volume":"123","author":"Illi","year":"2009","journal-title":"Pharmacol. Ther."},{"issue":"49","key":"10.1016\/j.ejmech.2021.113934_bib196","doi-asserted-by":"crossref","first-page":"19183","DOI":"10.1073\/pnas.0805514105","article-title":"HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment","volume":"105","author":"Colussi","year":"2008","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"issue":"1","key":"10.1016\/j.ejmech.2021.113934_bib197","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5582\/bst.2011.v5.1.17","article-title":"Expression, purification, and S-nitrosylation of recombinant histone deacetylase 8 in Escherichia coli","volume":"5","author":"Feng","year":"2011","journal-title":"Bioscience trends"},{"issue":"1","key":"10.1016\/j.ejmech.2021.113934_bib198","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/CIRCRESAHA.107.157305","article-title":"Nitric oxide modulates chromatin folding in human endothelial cells via protein phosphatase 2A activation and class II histone deacetylases nuclear shuttling","volume":"102","author":"Illi","year":"2008","journal-title":"Circ. Res."},{"issue":"16","key":"10.1016\/j.ejmech.2021.113934_bib199","doi-asserted-by":"crossref","first-page":"11004","DOI":"10.1074\/jbc.M112.441816","article-title":"A\u00a0nitric oxide-dependent cross-talk between class I and III histone deacetylases accelerates skin repair","volume":"288","author":"Spallotta","year":"2013","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2021.113934_bib200","article-title":"Roles and targets of class I and IIa histone deacetylases in cardiac hypertrophy","volume":"2011","author":"Kee","year":"2010","journal-title":"J.\u00a0Biomed. Biotechnol."},{"issue":"7211","key":"10.1016\/j.ejmech.2021.113934_bib201","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nature07238","article-title":"S-Nitrosylation of histone deacetylase 2 induces chromatin remodelling in neurons","volume":"455","author":"Nott","year":"2008","journal-title":"Nature"},{"issue":"15","key":"10.1016\/j.ejmech.2021.113934_bib202","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.1016\/j.bmc.2015.06.015","article-title":"Synthesis and biological evaluation of novel histone deacetylases inhibitors with nitric oxide releasing activity","volume":"23","author":"Duan","year":"2015","journal-title":"Bioorg. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2021.113934_bib203","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.chembiol.2014.02.013","article-title":"Neural crest development and craniofacial morphogenesis is coordinated by nitric oxide and histone acetylation","volume":"21","author":"Kong","year":"2014","journal-title":"Chem. Biol."},{"issue":"10","key":"10.1016\/j.ejmech.2021.113934_bib204","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/ni1001-907","article-title":"Nitric oxide and the immune response","volume":"2","author":"Bogdan","year":"2001","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.ejmech.2021.113934_bib205","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1023\/A:1005904704618","article-title":"Role of nitric oxide in mediation of macrophage cytotoxicity and apoptosis","volume":"17","author":"Albina","year":"1998","journal-title":"Cancer Metastasis Rev."},{"issue":"1","key":"10.1016\/j.ejmech.2021.113934_bib206","doi-asserted-by":"crossref","first-page":"116","DOI":"10.5483\/BMBRep.2002.35.1.116","article-title":"Nitric oxide as a pro-apoptotic as well as anti-apoptotic modulator","volume":"35","author":"Choi","year":"2002","journal-title":"BMB Reports"},{"issue":"32","key":"10.1016\/j.ejmech.2021.113934_bib207","doi-asserted-by":"crossref","first-page":"22994","DOI":"10.1016\/S0021-9258(18)50046-6","article-title":"Early loss of the tyrosyl radical in ribonucleotide reductase of adenocarcinoma cells producing nitric oxide","volume":"267","author":"Lepoivre","year":"1992","journal-title":"J.\u00a0Biol. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2021.113934_bib208","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.niox.2010.10.001","article-title":"Dual role of NO donors in the reversal of tumor cell resistance and EMT: downregulation of the NF-\u03baB\/Snail\/YY1\/RKIP circuitry","volume":"24","author":"Bonavida","year":"2011","journal-title":"Nitric Oxide"},{"issue":"2","key":"10.1016\/j.ejmech.2021.113934_bib209","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.niox.2008.04.018","article-title":"Novel therapeutic applications of nitric oxide donors in cancer: roles in chemo-and immunosensitization to apoptosis and inhibition of metastases","volume":"19","author":"Bonavida","year":"2008","journal-title":"Nitric Oxide"},{"issue":"4","key":"10.1016\/j.ejmech.2021.113934_bib210","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1200\/JCO.2005.04.0436","article-title":"Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB\/IV non\u2013small-cell lung cancer","volume":"24","author":"Yasuda","year":"2006","journal-title":"J.\u00a0Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ejmech.2021.113934_bib211","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/mutage\/gel051","article-title":"Mutagenesis induced by the nitric oxide donor sodium nitroprusside in mouse cells","volume":"22","author":"Lee","year":"2007","journal-title":"Mutagenesis"},{"issue":"1","key":"10.1016\/j.ejmech.2021.113934_bib212","doi-asserted-by":"crossref","DOI":"10.4155\/fso.15.44","article-title":"Nitric oxide for cancer therapy","volume":"1","author":"Huerta","year":"2015","journal-title":"Future science OA"},{"issue":"1","key":"10.1016\/j.ejmech.2021.113934_bib213","first-page":"1","article-title":"Nitric oxide and cancer: a review","volume":"11","author":"Choudhari","year":"2013","journal-title":"World J. Surg. Oncol."},{"key":"10.1016\/j.ejmech.2021.113934_bib214","series-title":"Nitric Oxide and Cancer: to Inhibit or to Induce iNOS: that Is the Question? Therapeutic Application of Nitric Oxide in Cancer and Inflammatory Disorders","first-page":"93","author":"Kashfi","year":"2019"},{"issue":"2","key":"10.1016\/j.ejmech.2021.113934_bib215","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.niox.2008.04.006","article-title":"Molecular mechanisms for discrete nitric oxide levels in cancer","volume":"19","author":"Ridnour","year":"2008","journal-title":"Nitric Oxide"},{"issue":"10","key":"10.1016\/j.ejmech.2021.113934_bib216","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1021\/ml400289e","article-title":"Synthesis and biological evaluation of the first example of NO-donor histone deacetylase inhibitor","volume":"4","author":"Borretto","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"issue":"3","key":"10.1016\/j.ejmech.2021.113934_bib217","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/stem.300","article-title":"Nitric oxide determines mesodermic differentiation of mouse embryonic stem cells by activating class IIa histone deacetylases: potential therapeutic implications in a mouse model of hindlimb ischemia","volume":"28","author":"Spallotta","year":"2010","journal-title":"Stem Cell."},{"issue":"12","key":"10.1016\/j.ejmech.2021.113934_bib218","first-page":"1285","article-title":"Nitric oxide does not mediate but inhibits transformation and tumor phenotype","volume":"2","author":"Dhar","year":"2003","journal-title":"Mol. Cancer Therapeut."},{"issue":"3","key":"10.1016\/j.ejmech.2021.113934_bib219","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1158\/1535-7163.MCT-07-2037","article-title":"Anticancer properties of the novel nitric oxide-donating compound (S, R)-3-phenyl-4, 5-dihydro-5-isoxazole acetic acid-nitric oxide in\u00a0vitro and in\u00a0vivo","volume":"7","author":"Maksimovic-Ivanic","year":"2008","journal-title":"Mol. Cancer Therapeut."},{"issue":"6","key":"10.1016\/j.ejmech.2021.113934_bib220","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/0006-2952(92)90379-W","article-title":"Thiol-mediated generation of nitric oxide accounts for the vasodilator action of furoxans","volume":"44","author":"Feelisch","year":"1992","journal-title":"Biochem. Pharmacol."},{"issue":"11","key":"10.1016\/j.ejmech.2021.113934_bib221","doi-asserted-by":"crossref","first-page":"4738","DOI":"10.1021\/jm400463q","article-title":"Novel hybrids of (phenylsulfonyl) furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer","volume":"56","author":"Han","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"issue":"15","key":"10.1016\/j.ejmech.2021.113934_bib222","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1021\/jm800167u","article-title":"Design, synthesis, and antihepatocellular carcinoma activity of nitric oxide releasing derivatives of oleanolic acid","volume":"51","author":"Chen","year":"2008","journal-title":"J.\u00a0Med. Chem."},{"issue":"7","key":"10.1016\/j.ejmech.2021.113934_bib223","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1021\/jm030544m","article-title":"Design and synthesis of 3 \u2018-and 5 \u2018-O-(3-Benzenesulfonylfuroxan-4-yl)-2 \u2018-deoxyuridines: biological evaluation as hybrid nitric oxide Donor\u2212 nucleoside anticancer agents","volume":"47","author":"Moharram","year":"2004","journal-title":"J.\u00a0Med. Chem."},{"issue":"10","key":"10.1016\/j.ejmech.2021.113934_bib224","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1016\/j.bmc.2010.03.077","article-title":"Synthesis and evaluation of nitric oxide-releasing derivatives of farnesylthiosalicylic acid as anti-tumor agents","volume":"18","author":"Ling","year":"2010","journal-title":"Bioorg. Med. Chem."},{"issue":"10","key":"10.1016\/j.ejmech.2021.113934_bib225","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1021\/acs.jmedchem.5b00317","article-title":"Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor","volume":"58","author":"Duan","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2021.113934_bib226","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s11094-008-0097-7","article-title":"Fungicidal and toxicological properties of functionally substituted nitrobenzofuroxanes","volume":"42","author":"Yusupova","year":"2008","journal-title":"Pharmaceut. Chem. J."},{"issue":"8","key":"10.1016\/j.ejmech.2021.113934_bib227","first-page":"1268","article-title":"Benzofuroxan derivatives as potent agents against multidrug-resistant","volume":"16","author":"Fernandes","year":"2021","journal-title":"Mycobacterium tuberculosis. ChemMedChem."},{"key":"10.1016\/j.ejmech.2021.113934_bib228","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.ejmech.2017.12.047","article-title":"Structural and biological characterization of new hybrid drugs joining an HDAC inhibitor to different NO-donors","volume":"144","author":"Atlante","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2021.113934_bib229","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s00392-007-0588-7","article-title":"New insights into bioactivation of organic nitrates, nitrate tolerance and cross-tolerance","volume":"97","author":"Daiber","year":"2008","journal-title":"Clin. Res. Cardiol."},{"key":"10.1016\/j.ejmech.2021.113934_bib230","unstructured":"Mozzetta AG, Illi B, Rosati J, Straino S, Ragone G, Pescatori M, et\u00a0al. How Do New Gene Clusters Form?, line 17, the reference callout \u2018\u2018(109\u2013111)\u2019\u2019should instead read \u2018\u2018(109\u2013111, 113).\u2019\u2019The added reference appears below. Microbiology.152:3517-3528."},{"issue":"25","key":"10.1016\/j.ejmech.2021.113934_bib231","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1021\/jm00025a012","article-title":"The furoxan system as a useful tool for balancing\" hybrids\" with mixed. Alpha. 1-Antagonist and NO-like vasodilator activities","volume":"38","author":"Fruttero","year":"1995","journal-title":"J.\u00a0Med. Chem."},{"issue":"7458","key":"10.1016\/j.ejmech.2021.113934_bib232","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nature12343","article-title":"Myomaker is a membrane activator of myoblast fusion and muscle formation","volume":"499","author":"Millay","year":"2013","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.ejmech.2021.113934_bib233","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1021\/acsmedchemlett.9b00643","article-title":"Synthesis and antiproliferative activity of nitric oxide-donor largazole prodrugs","volume":"11","author":"Borgini","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"issue":"3","key":"10.1016\/j.ejmech.2021.113934_bib234","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.3390\/md12031623","article-title":"Largazole pharmacokinetics in rats by LC-MS\/MS","volume":"12","author":"Yu","year":"2014","journal-title":"Mar. Drugs"},{"issue":"6","key":"10.1016\/j.ejmech.2021.113934_bib235","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1021\/ja7110064","article-title":"Structure and activity of largazole, a potent antiproliferative agent from the Floridian marine cyanobacterium Symploca sp","volume":"130","author":"Taori","year":"2008","journal-title":"J.\u00a0Am. Chem. Soc."},{"issue":"4","key":"10.1016\/j.ejmech.2021.113934_bib236","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/liv.12034","article-title":"A\u00a0histone deacetylase inhibitor, largazole, decreases liver fibrosis and angiogenesis by inhibiting transforming growth factor-\u03b2 and vascular endothelial growth factor signalling","volume":"33","author":"Liu","year":"2013","journal-title":"Liver Int."},{"issue":"3","key":"10.1016\/j.ejmech.2021.113934_bib237","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1021\/ml1002794","article-title":"In\u00a0vitro and in\u00a0vivo osteogenic activity of largazole","volume":"2","author":"Lee","year":"2011","journal-title":"ACS Med. Chem. Lett."},{"issue":"23","key":"10.1016\/j.ejmech.2021.113934_bib238","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1002\/cmdc.201700563","article-title":"Largazole analogues as histone deacetylase inhibitors and anticancer agents: an overview of structure\u2013activity relationships","volume":"12","author":"Poli","year":"2017","journal-title":"ChemMedChem"},{"issue":"6","key":"10.1016\/j.ejmech.2021.113934_bib239","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1021\/ol900078k","article-title":"Synthesis and histone deacetylase inhibitory activity of largazole analogs: alteration of the zinc-binding domain and macrocyclic scaffold","volume":"11","author":"Bowers","year":"2009","journal-title":"Org. Lett."},{"issue":"21","key":"10.1016\/j.ejmech.2021.113934_bib240","doi-asserted-by":"crossref","first-page":"7453","DOI":"10.1021\/jm200432a","article-title":"Largazole and analogues with modified metal-binding motifs targeting histone deacetylases: synthesis and biological evaluation","volume":"54","author":"Bhansali","year":"2011","journal-title":"J.\u00a0Med. Chem."},{"issue":"30","key":"10.1016\/j.ejmech.2021.113934_bib241","doi-asserted-by":"crossref","first-page":"7237","DOI":"10.1021\/ja9613724","article-title":"Total synthesis of the antitumor depsipeptide FR-901,228","volume":"118","author":"Li","year":"1996","journal-title":"J.\u00a0Am. Chem. Soc."},{"issue":"1","key":"10.1016\/j.ejmech.2021.113934_bib242","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1006\/excr.1998.4027","article-title":"FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor","volume":"241","author":"Nakajima","year":"1998","journal-title":"Exp. Cell Res."},{"issue":"6","key":"10.1016\/j.ejmech.2021.113934_bib243","doi-asserted-by":"crossref","first-page":"276","DOI":"10.5582\/ddt.2016.01067","article-title":"Nitric oxide donor hybrid compounds as promising anticancer agents","volume":"10","author":"Ding","year":"2016","journal-title":"Drug discoveries & therapeutics"},{"issue":"5","key":"10.1016\/j.ejmech.2021.113934_bib244","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.freeradbiomed.2007.04.026","article-title":"Methods to detect nitric oxide and its metabolites in biological samples","volume":"43","author":"Bryan","year":"2007","journal-title":"Free Radical Biol. Med."},{"issue":"2","key":"10.1016\/j.ejmech.2021.113934_bib245","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1124\/jpet.110.172387","article-title":"Anticolon cancer activity of largazole, a marine-derived tunable histone deacetylase inhibitor","volume":"335","author":"Liu","year":"2010","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"issue":"12","key":"10.1016\/j.ejmech.2021.113934_bib246","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1016\/j.bmc.2011.02.024","article-title":"Total synthesis of largazole and analogues: HDAC inhibition, antiproliferative activity and metabolic stability","volume":"19","author":"Benelkebir","year":"2011","journal-title":"Bioorg. Med. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2021.113934_bib247","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1089\/ars.2008.2234","article-title":"Nitric oxide in health and disease of the nervous system","volume":"11","author":"Knott","year":"2009","journal-title":"Antioxidants Redox Signal."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421007832?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421007832?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:36:20Z","timestamp":1759329380000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523421007832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":247,"alternative-id":["S0223523421007832"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.113934","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NO-HDAC dual inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.113934","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"113934"}}